Evaxion has embarked on a new initiative to develop a preventive vaccine targeting Group A Streptococcus (GAS), a bacterium responsible for hundreds of millions of infections worldwide annually. These infections can lead to severe complications, including conditions such as rheumatic heart disease, necrotizing fasciitis, as well as other serious illnesses like strep throat and scarlet fever. The new vaccine project, titled EVX-B4, is a recent addition to Evaxion's research and development efforts, which focus on vaccines for cancer and infectious diseases.
Initial computational studies have shown that AI-Immunology possesses the capacity to pinpoint novel vaccine targets against GAS. This innovative approach could revolutionize the fight against the bacterium. By utilizing AI-Immunology, Evaxion can expedite the discovery, design, and validation of targets, thereby accelerating the preclinical development of EVX-B4. The aim is to compile a comprehensive set of preclinical data to support future partnership opportunities. (EVAX, Financial) is actively pushing forward in the landscape of vaccine development through this cutting-edge project.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Evaxion AS (EVAX, Financial) is $31.92 with a high estimate of $70.00 and a low estimate of $6.00. The average target implies an upside of 1,202.72% from the current price of $2.45. More detailed estimate data can be found on the Evaxion AS (EVAX) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Evaxion AS's (EVAX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
EVAX Key Business Developments
Release Date: May 27, 2025
- Cash Position: EUR17.8 million, up from EUR6 million at the end of 2024.
- Operational Cash Burn: Estimated at EUR14 million for the year.
- Cash Runway: Until mid-2026.
- Operating Loss: EUR3.9 million, compared to EUR4.4 million last year.
- Net Loss: EUR1.6 million, compared to a net income of EUR1.2 million last year.
- Financial Income: EUR2.4 million from reassessment of a derivative liability.
- Total Equity: EUR10.3 million, a significant increase from the end of 2024.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Evaxion AS (EVAX, Financial) has made strong progress across all parts of the business, including a solid business development pipeline.
- The partnership with Merck is on track, with a potential $10 million milestone if Merck exercises options in the second half of the year.
- EVX-01, a personalized cancer vaccine, is yielding positive data, with 80% of new antigens eliciting an immune response.
- Evaxion AS (EVAX) has a cash runway until mid-2026, providing financial stability for ongoing projects.
- The company has strengthened its equity position significantly, with a cash position of EUR17.8 million, up from EUR6 million at the end of 2024.
Negative Points
- The current turmoil in financial markets and increased regulatory uncertainty are impacting deal execution, with some potential partners pausing discussions.
- There is a risk of increased project costs in upcoming quarters, as spending is expected to pick up.
- The company recorded an operating loss of EUR3.9 million in Q1 2025, although this is an improvement from the previous year.
- Evaxion AS (EVAX) faces challenges with derivative liabilities due to currency exchange rates, which may impact financial results in future quarters.
- Despite positive developments, the company remains exposed to macroeconomic risks that could affect its business development targets.
